Wouter de Herder explains the critical role of endocrinology in managing patients with neuroendocrine neoplasms, the principles of somatostatin analog therapy and identifies the groups of neuroendocrine tumor (NET) patients who benefit most from it, the recommended second-line treatment for patients with advanced, unresectable, or metastasized gastroentero-pancreatic NET after recurrence with somatostatin analogs, and the main highlights from ENETS 2024.

Julien Hadoux describes various ways to improve the early and accurate diagnosis and treatment of patients with neuroendocrine tumors (NETs), the present and future aspects of molecular profiling in the management of NETs, the use of radiopharmaceutical therapy (RPT) compared to other systemic targeted therapies in the treatment sequence of patients with NETs, and the main highlights from ENETS 2024. 

Paola Erba discusses the use of FDG PET/CT in conjunction with somatostatin receptor imaging for the initial staging of patients with neuroendocrine tumors, how the recent developments in theranostics have influenced guidelines and recommendations for treating neuroendocrine tumors (NETs), the challenges and needs for expanding access to radiopharmaceutical treatment (RPT), and the main highlights from the ENETS 2024.